Fujian Haixi Pharmaceuticals Co., Ltd. (HKG:2637)
Hong Kong flag Hong Kong · Delayed Price · Currency is HKD
136.50
+0.50 (0.37%)
At close: Feb 13, 2026

HKG:2637 Income Statement

Millions CNY. Fiscal year is Jan - Dec.
Fiscal Year
FY 2024FY 2023FY 2022
Period Ending
Dec '24 Dec '23 Dec '22
466.68316.63212.47
Revenue Growth (YoY)
47.39%49.03%-
Cost of Revenue
79.4952.9940.39
Gross Profit
387.19263.64172.07
Selling, General & Admin
186.64107.356.9
Research & Development
67.5336.0634.82
Operating Expenses
254.17143.3691.72
Operating Income
133.03120.2880.35
Interest Expense
-7.22-7.75-24.73
Interest & Investment Income
5.647.096.39
Other Non Operating Income (Expenses)
16.4113.2311.92
EBT Excluding Unusual Items
147.85132.8573.92
Gain (Loss) on Sale of Investments
1.14--0.14
Gain (Loss) on Sale of Assets
--0.03-0.02
Pretax Income
148.99132.8173.76
Income Tax Expense
12.9215.364.78
Net Income
136.08117.4568.98
Net Income to Common
136.08117.4568.98
Net Income Growth
15.86%70.27%-
Shares Outstanding (Basic)
676764
Shares Outstanding (Diluted)
676764
Shares Change (YoY)
-4.57%-
EPS (Basic)
2.021.751.07
EPS (Diluted)
2.021.751.07
EPS Growth
15.86%62.83%-
Free Cash Flow
-14.6288.3982.24
Free Cash Flow Per Share
-0.221.311.28
Gross Margin
82.97%83.26%80.99%
Operating Margin
28.51%37.99%37.82%
Profit Margin
29.16%37.09%32.47%
Free Cash Flow Margin
-3.13%27.92%38.71%
EBITDA
135.96122.6182.23
EBITDA Margin
29.13%38.72%38.70%
D&A For EBITDA
2.932.331.88
EBIT
133.03120.2880.35
EBIT Margin
28.51%37.99%37.82%
Effective Tax Rate
8.67%11.56%6.48%
Source: S&P Global Market Intelligence. Standard template. Financial Sources.